Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2357269rdf:typepubmed:Citationlld:pubmed
pubmed-article:2357269lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:2357269lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:2357269lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:2357269lifeskim:mentionsumls-concept:C0752105lld:lifeskim
pubmed-article:2357269lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:2357269lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:2357269pubmed:issue1lld:pubmed
pubmed-article:2357269pubmed:dateCreated1990-8-2lld:pubmed
pubmed-article:2357269pubmed:abstractTextFour youngsters, between the ages of 13-27 years, presented dystonic foot. Two to three years following the appearance of the dystonic foot, cogwheel rigidity and tremor appeared on the dystonic foot side. Treatment with low doses of levodopa/carbidopa consistently reversed the symptoms. "On-off" phenomena appeared in the first years of treatment and persisted for the entire period of 5 to 15 years of illness. No parkinsonian signs were present when the dystonic foot appeared. Based on our observations and on a review of the literature, we conclude that responsiveness to low doses of L-dopa is the major marker of juvenile Parkinson's disease.lld:pubmed
pubmed-article:2357269pubmed:languageenglld:pubmed
pubmed-article:2357269pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2357269pubmed:citationSubsetIMlld:pubmed
pubmed-article:2357269pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2357269pubmed:statusMEDLINElld:pubmed
pubmed-article:2357269pubmed:issn0936-3076lld:pubmed
pubmed-article:2357269pubmed:authorpubmed-author:AskenasyJ JJJlld:pubmed
pubmed-article:2357269pubmed:authorpubmed-author:MendelsonLLlld:pubmed
pubmed-article:2357269pubmed:authorpubmed-author:KerenOOlld:pubmed
pubmed-article:2357269pubmed:authorpubmed-author:BraunZZlld:pubmed
pubmed-article:2357269pubmed:issnTypePrintlld:pubmed
pubmed-article:2357269pubmed:volume2lld:pubmed
pubmed-article:2357269pubmed:ownerNLMlld:pubmed
pubmed-article:2357269pubmed:authorsCompleteYlld:pubmed
pubmed-article:2357269pubmed:pagination23-30lld:pubmed
pubmed-article:2357269pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:2357269pubmed:meshHeadingpubmed-meshheading:2357269-...lld:pubmed
pubmed-article:2357269pubmed:meshHeadingpubmed-meshheading:2357269-...lld:pubmed
pubmed-article:2357269pubmed:meshHeadingpubmed-meshheading:2357269-...lld:pubmed
pubmed-article:2357269pubmed:meshHeadingpubmed-meshheading:2357269-...lld:pubmed
pubmed-article:2357269pubmed:meshHeadingpubmed-meshheading:2357269-...lld:pubmed
pubmed-article:2357269pubmed:meshHeadingpubmed-meshheading:2357269-...lld:pubmed
pubmed-article:2357269pubmed:meshHeadingpubmed-meshheading:2357269-...lld:pubmed
pubmed-article:2357269pubmed:meshHeadingpubmed-meshheading:2357269-...lld:pubmed
pubmed-article:2357269pubmed:year1990lld:pubmed
pubmed-article:2357269pubmed:articleTitleJuvenile Parkinson's disease and its response to L-dopa therapy.lld:pubmed
pubmed-article:2357269pubmed:affiliationLoewenstein Rehabilitation Hospital, Tel-Aviv University, Israel.lld:pubmed
pubmed-article:2357269pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2357269pubmed:publicationTypeCase Reportslld:pubmed